source
- Arrowhead’s plozasiran shows favorable safety in severe hypertriglyceridemia late-stage trialsArrowhead presented late-stage data for its RNA interference therapy plozasiran, marketed as Redemplo, in severe hypertriglyceridemia at the European Society of Cardiology 2026 meeting in Munich.…
- Verily, NVIDIA and NIH launch first multimodal AI model combining EHR and genomicsVerily Health, in partnership with NVIDIA and the NIH All of Us Research Program, announced the development of a new foundation model that merges electronic health record data with genomic informat…